drugset / Trial / NCT00246623

US Inhaled Insulin Dose Titration Study

NCT00246623

Phase 3 Completed 120 enrolled Pfizer Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study.

Timeline

Start
2005-11
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled